These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 17891013

  • 1. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S.
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Oct; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
    Chen E, Kaiser RS, Vander JF.
    Retina; 2007 Jun; 27(4):445-50. PubMed ID: 17420696
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F, Eid Farah M, Melo GB.
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract] [Full Text] [Related]

  • 8. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 9. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK.
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 12. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Mar; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 13. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.
    BMC Ophthalmol; 2007 Jun 07; 7():10. PubMed ID: 17555600
    [Abstract] [Full Text] [Related]

  • 14. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun 07; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ.
    Retina; 2006 Apr 07; 26(4):383-90. PubMed ID: 16603955
    [Abstract] [Full Text] [Related]

  • 16. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug 07; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Am J Ophthalmol; 2007 Jun 07; 143(6):977-983. PubMed ID: 17459318
    [Abstract] [Full Text] [Related]

  • 18. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R, Soliman W, Lund-Andersen H, Larsen M.
    Acta Ophthalmol Scand; 2007 Aug 07; 85(5):526-33. PubMed ID: 17511757
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 Aug 07; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM, Falcão MS, Brandão EM, Falcão-Reis FM.
    Retina; 2010 Jan 07; 30(1):85-92. PubMed ID: 20010320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.